Sorry my posts may confuse you, I really appreciate CVM longs
or any other biotech longs I follow posting their view to help
other like me. I have a small problem in writing as you notice.
I am trying to figure out why CEO Geert wants to PR the complete
data at first PR, which is against norms of biotech releasing
topline first and presenting full data at peer reviewed conference.
CVM can notify FDA right after receiving the data set, no conflict
of PR the complete data to the public too because CVM does not need
FDA's OK to PR the data, IMO. What ever the final results are set
in stone now, no matter of when and how the PR comes out, Good luck
CVM longs!
News 
Market Data 
Discover 
